Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (7)
2021
-
An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177
-
OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors
Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472
2020
-
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460
2018
-
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
Nature Communications, Vol. 9, Núm. 1
2014
-
Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours
Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 322-329
2012
-
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies
OncoImmunology, Vol. 1, Núm. 8, pp. 1344-1354
2011
-
New trends in immunotherapy
Inmunologia